发明名称 |
Use of soluble forms of the Desmoglein I protein for the purposes of screening for anti-ageing active agents |
摘要 |
The invention relates to the use of one or more complexed or noncomplexed, soluble peptide form(s) of Desmoglein I, as a marker for evaluating the effectiveness of active agents and/or of treatments, in particular anti-ageing active agents and/or treatments, with regard to an epidermis. |
申请公布号 |
US9316653(B2) |
申请公布日期 |
2016.04.19 |
申请号 |
US201012687601 |
申请日期 |
2010.01.14 |
申请人 |
L'OREAL |
发明人 |
Donovan Mark;Simonetti Lucie;Bernard Dominique |
分类号 |
G01N31/00;G01N33/53;G01N33/68;A61K8/64;A61Q19/08 |
主分类号 |
G01N31/00 |
代理机构 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
代理人 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
主权项 |
1. A method for characterizing the effectiveness of a cosmetic treatment intended, in an individual having an epidermis showing one or more signs of skin ageing, to compensate the accumulation of desmoglein I in the stratum corneum, the method comprising:
a) after administering the cosmetic treatment, obtaining a skin sample from the individual; b) quantifying at least one soluble peptide form with an anti-desmoglein I antibody, wherein the soluble peptide derives at least in part from the proteolysis of a polypeptide comprising an amino acid sequence represented by part of SEQ ID NO:2; and c) comparing the content obtained in step b) with a reference value obtained from a cosmetically untreated skin sample, and the presence or increase in the soluble peptide form content with respect to the reference value being indicative of a release of desmoglein I from the stratum corneum, and said release of desmoglein I being indicative of an effectiveness of the cosmetic treatment. |
地址 |
Paris FR |